Nymox's NicAlert Helps Physicians Determine Tobacco Smoke Exposure and Smoking Status of Their Patients
MAYWOOD, N.J.--(BUSINESS WIRE)--Nov. 14, 2002--Nymox Pharmaceutical Corporation's NicAlert(TM) provides physicians and nurses with a simple, convenient and cost-effective means of quickly and accurately determining tobacco smoke exposure and the smoking s
This test is particularly important for those patients at heightened risk from smoking, such as pregnant women, patients with high blood pressure and asthmatics.
NicAlert(TM) is a powerful one-step patented urine test for detecting smoking and tobacco product exposure that combines the advantages of semi-quantitative measurement together with an easy-to-use, cost effective, rapid format. NicAlert(TM) does not require any instruments or special training for its use.
NicAlert(TM) received 510(k) clearance from the U.S. FDA in October, 2002.
Michael Munzar, Medical Director of Nymox, said, "Over the past ten years, there has been an increased awareness about the need for physicians to ask their patients about smoking status and to advise and assist them about smoking cessation. Smoking is the single most preventable cause of death in our society today. NicAlert(TM) offers physicians a simple on-site method of determining and monitoring the smoking status of their patients."
Physicians should routinely assess, review and document the smoking status of every patient, according to A Clinical Practice Guideline for Treating Tobacco Use and Dependence (JAMA 2000; 283:3244-54) issued by the U.S. Public Health Service and formal policy positions adopted by the American Medical Association, the American Heart Association, the American Academy of Family Physicians and other medical associations.
For some patients, an accurate determination of smoking status is particularly important. Smoking is even more of a health risk for pregnant women (being associated with miscarriage, stillbirth and low birth weight among other deleterious effects), for people with high blood pressure (increasing the risk of stroke and heart attack) and for asthmatics (triggering asthma attacks and lowering lung function).
Studies have shown that a significant percentage of patients at risk do not always truthfully report their smoking status.
The Nymox patented technology is used in two tobacco exposure products, NicAlert(TM) and Nicometer(TM), to provide rapid, semi-quantitative measures of levels of tobacco product and tobacco smoke exposure.
Two recent independent peer-reviewed studies found the Nymox technology to be an accurate, rapid and cost-effective means of confirming smoking status. One study, "Validating a Dipstick Method for Detecting Recent Smoking," Cancer Epidemiology, Biomarkers & Prevention (2002; 11: 1123-1125) was authored by Peter Gariti of the University of Pennsylvania Cancer Center Group, Philadelphia Veterans Affairs Medical Center and the University of Pennsylvania School of Medicine, David I. Rosenthal of the M.D. Anderson Cancer Center in Houston, Kathleen Lindell of the University of Pittsburgh and John Hansen-Flaschen, Joseph Shrager, Craig Lipkin, Arthur I. Alterman and Lawrence R. Kaiser of the University of Pennsylvania School of Medicine. The study examined the smoking status of patients at a cancer clinic and found that the results obtained using Nicometer(TM) had an "excellent agreement" with state-of-the-art sophisticated laboratory measurements but at a substantially lower cost (over 90% less). The second study, "The Accuracy of Self-Reported Smoking Status Assessed by Cotinine Test Strips," Nicotine & Tobacco Research (2002; 4: 305-9) was authored by Donna R. Parker, ScD, and Thomas M Lasater, PhD, Brown University School of Medicine; Richard Windsor, PhD, MPH, George Washington University Medical Center; Jeff Wilkins, MD, Greater Los Angeles VA Healthcare Center, David Upegui, BA, Memorial Hospital of Rhode Island; and James Heimdal, PhD, The Hoffman Heart Institute, Saint Francis Hospital and Medical Center, Hartford, CT. The study found Nicometer(TM) to be "an inexpensive and rapid method to routinely biochemically confirm smoking status at a clinical visit." The authors described Nicometer(TM) as "simple, inexpensive and rapid measure to immediately confirm smoking status in field settings."
NicAlert(TM) was recently used in a nationwide stop-smoking campaign in Switzerland jointly run by the Swiss Federal Office of Public Health, the Swiss Association for Smoking Prevention, the Swiss League Against Cancer and the Swiss Lung Association. The test is currently being used in large studies at the Lung-Center Hirslanden in Zurich, Switzerland, and in many large U.S. centers.
The U.S. Surgeon General, the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO) and many other public health organizations have targeted tobacco use as the single most preventable cause of premature death today. The CDC estimates that smoking causes over 440,000 premature deaths annually in the United States and creates an economic loss of over $150 billion a year.
More information about Nymox is available at www.nymox.com, email: email@example.com, or 800-936-9669.
This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.